Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Huang, Xin  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
He D, Zhu C, Guo X, Huang X, Han X, Zheng G, Zhao Y, Yang Y, Wu W, Ge J, et al. The efficacy of residual plerixafor for second-day stem cell mobilization in multiple myeloma patients. Transfus Apher Sci. 2022:103618.
Li D, Yang J, Huang X, Zhou H, Wang J. eIF4A2 targets developmental potency and histone H3.3 transcripts for translational control of stem cell pluripotency. Sci Adv. 2022;8(13):eabm0478.
Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q, Tao Q. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget. 2016.
Zhang P, Gan Z, Tang L, Zhou L, Huang X, Wang J. Exosomes from microRNA-145-5p-modified HUCB-MSCs attenuate CCl4-induced hepatic fibrosis via down-regulating FSCN1 expression. Life Sci. 2021:119404.
Guo L, Lai P, Wang Y, Huang T, Chen X, Geng S, Huang X, Luo C, Wu S, Ling W, et al. Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response. Int Immunopharmacol. 2020;84:106541.
Guo L, Lai P, Wang Y, Huang T, Chen X, Luo C, Geng S, Huang X, Wu S, Ling W, et al. Extracellular vesicles from mesenchymal stem cells prevent contact hypersensitivity through the suppression of Tc1 and Th1 cells and expansion of regulatory T cells. Int Immunopharmacol. 2019;74:105663.

Pages